Skye Bioscience, Inc. (SKYE): R&D Expense
$42.36M
Year ended 2025-12-31
$32.70M
Trailing 12 months to 2026-06-30
+91.7%
3-year compound annual growth
+85.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.36M | +126.5% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $18.70M | +221.4% | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $5.82M | -3.2% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $6.01M | +105.1% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $2.93M | +50.8% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $1.94M | -13.1% | 2022-03-28, From 2020-01-01 |
| 2019-12-31 | $2.24M | +578.2% | 2021-03-02, From 2019-01-01 |
| 2018-12-31 | $330.0K | +6.0% | 2020-03-23, From 2018-01-01 |
| 2017-12-31 | $311.3K | -66.8% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $939.0K | +63.0% | 2018-03-19, From 2016-01-01 |
| 2015-12-31 | $576.1K | +153.2% | 2017-03-10, From 2015-01-01 |
| 2014-12-31 | $227.5K | n/a | 2016-03-21, From 2014-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $42.36M | +126.5% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $3.72M | +78.0% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $20.53M | +54.0% |
| Aptevo Therapeutics Inc. (APVO) | 2025-12-31 | $14.54M | +1.1% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $6.03M | -10.2% |
| Veru Inc. (VERU) | 2025-09-30 | $15.59M | +22.0% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.80M | +28.1% |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $604.3K | -35.3% |
Compare SKYE, BFRI, NEUP, HURA side by side · Screen every company in Pharmaceutical Preparations ↗